Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Aggregate statistics from Disclosed's verified COA corpus. All numbers are computed directly from lab-uploaded Certificates of Analysis — no editorial claims, no estimates.
COAs
5
Labs
4
Vendors tested
3
Avg purity
99.5%
±0.3%
Endotoxin tested
40%
of all COAs tested
Sterility tested
0%
of all COAs tested
Methodology:Purity averages exclude values outside [50%, 100%] to filter unit misreads. "Vendors tested" counts distinct vendor IDs across all in-scope, non-withdrawn, extracted COAs. Endotoxin/sterility coverage denominators are all in-scope COAs (not filtered to parenteral form).
Data updates hourly. All figures are computed from lab-uploaded COAs; Disclosed does not perform independent testing.
Based on 5 Certificates of Analysis in the Disclosed corpus, FOXO4-DRI has an average HPLC purity of 99.5% (±0.3% std dev). This figure spans 3 vendors tested across 4 independent labs. Purity is measured by high-performance liquid chromatography (HPLC); values outside 50–100% are excluded as unit misreads.
4 distinct testing labs have produced COAs for FOXO4-DRI in the Disclosed database, covering 5 total tests across 3 vendors.
40% of FOXO4-DRI COAs in the Disclosed corpus include endotoxin test results (USP <85>), and 0% include sterility results (USP <71>). Endotoxin and sterility testing matter for injectable-grade peptides — their absence in a COA does not indicate failure, but absence is common in HPLC-only testing workflows.
Disclosed Labs